Boosting Biomedical Innovation: Indian Council of Medical Research (ICMR)'s 'Medical Innovations Patent Mitra' Launched! 🚀 This is set to revolutionize India's healthcare innovation ecosystem. Key takeaways: - 🌟 End-to-End Support: The initiative provides comprehensive guidance for patent filings and technology transfer, bridging gaps in the patenting process. This support ensures that innovators receive expert assistance at every stage, from assessing patentability to maintaining patents, fostering a seamless journey from idea to market. - 🌟 Expert Assistance: Offers support from patentability assessments to filing, prosecution, and maintenance, ensuring innovators are backed at every stage. - 🌟 Collaborative Effort: Developed under NITI Aayog Official's guidance, this initiative fosters a robust innovation environment. The collaboration between government bodies and industry leaders strengthens the ecosystem, promoting synergy and shared goals. Market Statistics: - 📈 Growth Potential: Aims for a tenfold increase in life science patents filed in India within the next two years. This ambitious target underscores the initiative's potential to drive significant growth in the biomedical sector, positioning India as a global innovation hub. - 🏥 Broad Impact: Supports ICMR Institutes, extramural grantees, and medical colleges, amplifying the reach of innovative solutions. By extending support to a wide range of institutions, the initiative ensures that cutting-edge research translates into practical applications, benefiting public health nationwide. Startup Opportunities - 💡 Innovation Protection: Utilize the platform to safeguard groundbreaking research and innovations through patents. Protecting intellectual property is crucial for startups to attract investment and scale their innovations. - 🤝 Seamless Technology Transfer: Leverage mechanisms like Med Tech "Mela" and paperless EoI processes for efficient industry collaboration. These mechanisms facilitate the transfer of technology from labs to the market, ensuring that innovations reach those who need them most. - 🌐 Global Reach: Transform innovative biomedical research into practical public health solutions with global potential. By fostering an environment conducive to innovation, India can lead the way in developing solutions that address global health challenges. This initiative propels India towards becoming a self-reliant nation in biomedical innovation, aligning with the goals of Ayushman Bharat and Viksit Bharat. Startups can drive this transformation, contributing to a sustainable and innovative healthcare ecosystem. The focus on self-reliance and indigenous innovation strengthens India's position in the global healthcare market, fostering economic growth and improved health outcomes. *Embrace the future of healthcare innovation!*

Apollo Hospitals has rolled out India’s first-ever Pediatric ProHealth Programme, a major step toward tackling the growing wave of non-communicable diseases (NCDs) among children. 🧬🩺 🔍 What’s Unique? The program is customized based on each child’s age and family medical history It targets early detection of lifestyle-related conditions such as obesity, diabetes, and hypertension Combines preventive screenings, pediatric consultations, and wellness guidance 💡 Why It Matters: With kids increasingly exposed to unhealthy diets, screen time, and sedentary lifestyles, this program marks a proactive shift from treatment to prevention in pediatric healthcare. 🗣️ Apollo's leadership emphasized that investing in a child's health today is an investment in the nation’s future well-being.

India is increasingly becoming a preferred destination for the global pharmaceutical supply chain, according to a recent report by Macquarie. The country’s strong manufacturing capabilities, cost efficiency, and regulatory reforms are driving its growth in the sector. The report highlights that India’s pharmaceutical industry, already valued at over $50 billion, is poised for further expansion as global companies seek to reduce dependence on China. With a well-established ecosystem of raw material suppliers, skilled workforce, and world-class production facilities, India offers a competitive edge in active pharmaceutical ingredients (APIs) and generic medicines. Government initiatives such as the Production-Linked Incentive (PLI) scheme and policy support for domestic API production have further strengthened India’s position. Additionally, rising investments in research and development (R&D) and the adoption of advanced technologies, including AI-driven drug discovery and digital healthcare solutions, are making India an attractive hub for global pharma giants. With increasing partnerships, export growth, and a favorable policy landscape, India is set to play a crucial role in ensuring a resilient and diversified global pharmaceutical supply chain. As multinational firms continue to shift their sourcing strategies, India stands out as a key beneficiary of this transformation. #PharmaceuticalIndustry #IndiaPharma #GlobalSupplyChain #APIs #DrugManufacturing #HealthcareInnovation #MedTech #PharmaGrowth #MakeInIndia #PLI #HealthcareStartups #DigitalHealth #Biopharma #R&D #AIinHealthcare #PharmaExports #SupplyChainResilience #HealthcareTech #Dseidehealthcarenetwork Source: Financial Express

Higher tariffs imposed by the U.S. on certain pharmaceutical imports from India are unlikely to impact the country’s competitive edge in the American market, according to industry experts. India remains a dominant player in the U.S. pharmaceutical sector, supplying around 40% of generic drugs. Factors such as cost-efficient manufacturing, a skilled workforce, and regulatory compliance continue to support India’s strong market presence. While the Biden administration has increased tariffs on some Chinese pharmaceutical ingredients, India is seen as a reliable alternative for drug production. The Indian pharmaceutical industry has also been expanding its manufacturing capabilities, reducing dependence on Chinese raw materials. This shift enhances supply chain resilience and ensures steady exports to the U.S. Industry leaders believe that India’s ability to produce affordable, high-quality medicines will help it withstand tariff changes. Additionally, ongoing investments in research and development (R&D), innovation, and adherence to U.S. FDA standards reinforce India’s position as a preferred supplier. Despite potential short-term cost pressures, Indian pharmaceutical firms are expected to remain competitive by leveraging economies of scale and focusing on high-value drug formulations. The long-term outlook remains positive, driven by global demand for affordable medicines and strong bilateral trade relations. #IndiaPharma #USPharmaMarket #GenericDrugs #PharmaExports #TradeRelations #HealthcareIndustry #MedTech #Tariffs #PharmaManufacturing #SupplyChain #AffordableMedicine #PharmaInnovation #DrugSupply #FDACertified #HealthTech #GlobalPharma #PharmaceuticalIndustry #dseidehealthcarenetwork Source: Financial Express

I got 30 registrations in 2 days For my 15-day free workshop For admins, managers & Marketers. I then spent years mastering the 7 strategies That made me 8-Figure Income in journy. That I’m giving away for FREE Comment “DM” and I’ll send the link. Here’s what you’ll learn: → 7 strategies to scale hospitals → Double revenue without extra cost → Fix staff, quality & operations → Master marketing & sales → Transform hospitals with proven methods And this isn’t random advice It’s trained on ↳ ₹50 lakh+ investment in research ↳ 19+ years in the healthcare industry ↳ Real case studies & tested tactics Then you simply 1. Join the free workshop 2. Learn the 7 strategies 3. Apply them & see results Want in? Comment “DM”. (Strictly limited to 50 people)

₹𝟭𝟮 𝗟𝗮𝗸𝗵 𝗧𝗮𝘅-𝗙𝗿𝗲𝗲 ₹𝟵𝟵,𝟴𝟱𝟴.𝟱𝟲 𝗰𝗿 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗜𝘀 𝘁𝗵𝗶𝘀 𝗿𝗲𝗮𝗹𝗹𝘆 𝗲𝗻𝗼𝘂𝗴𝗵 𝗳𝗼𝗿 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆? The government claims this budget provides relief. But does it? While tax exemption sounds good, But → Private doctors → Hospitals → Healthcare entrepreneurs Are still struggling with financial burdens. Here’s the reality: 𝗧𝗵𝗲 𝗜𝗹𝗹𝘂𝘀𝗶𝗼𝗻 𝗼𝗳 𝗧𝗮𝘅 𝗥𝗲𝗹𝗶𝗲𝗳 ↳ Private doctors still pay heavy operational costs with no deductions. 𝗥𝗶𝘀𝗶𝗻𝗴 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝘀𝘁𝘀 ↳ Hospitals face soaring expenses with zero incentives for growth. 𝗗𝗲𝗹𝗮𝘆𝗲𝗱 𝗣𝗮𝘆𝗺𝗲𝗻𝘁𝘀 & 𝗜𝗻𝘀𝘂𝗿𝗮𝗻𝗰𝗲 𝗜𝘀𝘀𝘂𝗲𝘀 ↳ Government schemes delay reimbursements, crushing cash flow. 𝗡𝗼 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗥𝘂𝗿𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 ↳ Doctors in smaller cities get no tax relief or infrastructure support. 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗘𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗮 𝗗𝗲𝗯𝘁 𝗧𝗿𝗮𝗽 ↳ Young doctors graduate with massive loans and no financial aid. 𝗡𝗼 𝗜𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗦𝘁𝗮𝗿𝘁𝘂𝗽𝘀 ↳ Medical entrepreneurs get no tax breaks or easy funding. 𝗨𝗻𝗱𝗲𝗿𝘄𝗵𝗲𝗹𝗺𝗶𝗻𝗴 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗕𝘂𝗱𝗴𝗲𝘁 ↳ ₹99,000 crore isn’t enough to expand or improve public health infrastructure. And that’s just the beginning. The budget does little to address the real struggles of healthcare professionals. Instead of superficial relief, we need: ✔️ Tax deductions for medical expenses & hospital investments. ✔️ Faster payments from insurance & government schemes. ✔️ Incentives for rural doctors & hospital expansion. ✔️ Affordable medical education & loan waivers. ✔️ Easier financing for healthcare businesses & startups. The ₹12 lakh exemption is just a headline—real solutions are missing. Ready to rethink your healthcare strategy in 2025? 𝗟𝗲𝘁’𝘀 𝘁𝗮𝗹𝗸.

𝗔𝗱𝗱𝗶𝗻𝗴 𝗜𝗨𝗜 𝗦𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗪𝗶𝘁𝗵𝗼𝘂𝘁 𝗣𝗿𝗶𝗼𝗿 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: 𝗛𝗲𝗿𝗲'𝘀 𝗛𝗼𝘄 𝗪𝗲 𝗗𝗶𝗱 𝗜𝘁 When expanding services, it's easy to feel like you're entering uncharted waters. Here’s a story: A clinic I worked with recently wanted to add Intrauterine Insemination (IUI) services. Their challenge? They had no prior expertise in this specific area. 𝗛𝗲𝗿𝗲’𝘀 𝘁𝗵𝗲 𝗽𝗿𝗼𝗯𝗹𝗲𝗺: Scaling services often feels risky when: You lack technical know-how. You fear the learning curve will hurt patient outcomes. You worry about the investment with no guaranteed ROI. 𝗛𝗲𝗿𝗲’𝘀 𝘄𝗵𝗮𝘁 𝘄𝗲 𝗿𝗲𝗮𝗹𝗶𝘇𝗲𝗱: The key wasn’t reinventing the wheel—it was finding the right partner. 𝗪𝗵𝗮𝘁 𝘄𝗲 𝗱𝗶𝗱: Partnered with a team of IUI specialists who had both the skills and tools to streamline the process. Built a step-by-step implementation plan tailored to the clinic’s existing workflow. Trained their staff on the nuances of IUI without overwhelming them. Used data to measure progress and refine the process in real-time. 𝗧𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀? A seamless integration of IUI services. Increased patient retention due to a broader range of offerings. A team more confident in delivering results, even in new areas. 𝗧𝗵𝗲 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆? You don’t need to be the expert to offer something new. Partnering smartly and building a system can open doors to growth without sacrificing quality. If you're considering adding IUI or similar services, start by asking yourself: Who can I collaborate with to make this a win for everyone?

Firms who require any investments , clients networking also can approach us, # investments, #clients networking@ advaithglobalservices

See who's building a community with us today ! We’re thrilled to announce that the Manipal-GoK Bioincubator has officially joined the Dseide Healthcare Network and established their own exclusive community ! This incredible initiative, a collaboration between Manipal Academy of Higher Education (MAHE) and the Government of Karnataka, is committed to fostering innovation and supporting startups in the healthcare and biotech sectors. The Bioincubator offers an exceptional platform for startups, entrepreneurs, researchers, faculty, and students to transform their groundbreaking ideas into reality. With access to world-class bio-incubation facilities, expert mentorship, cutting-edge infrastructure, and a strong focus on investment readiness and business validation, they are driving early-stage ideas toward successful commercialization. We are proud to provide them with an exclusive community on the DSEIDE Healthcare Network, designed to enhance collaboration, networking, and innovation within their ecosystem. Who will be the next to establish their community on the DSEIDE Healthcare Network? 💡 Join now [ManipalBioincubator] and unlock unparalleled opportunities for growth and collaboration ! Dr. Manesh Thomas Krishna P Bhat Dr. Clavian Larry Miranda Dheeraj Poojary SUDEEP R SHETTY [nikhila] [IshikaSinghCoordinator] [PreranaMCoordinator] M Dr. Komal Rana [Bharath_dseide] hashtag#healthcareincubator hashtag#healthcarestartups hashtag#healthcarestartup hashtag#healthcareinnovation hashtag#startup hashtag#startupecosystem hashtag#startupbanaglore

🚀 SUBHAG® HealthTech Secures Trademarks for V Conceive: A Game-Changer in Assisted Reproductive Technology! 🏆 We’re thrilled to announce that Subhag Healthtech has successfully secured trademarks for V CONCEIVE Home Insemination KIT, our groundbreaking, home-use insemination kit designed to offer an innovative approach to assisted reproduction. 🔬 Why This Matters: The global ART market is projected to grow at a CAGR of 6.3%, driven by rising infertility rates and increasing patient demand for non-invasive solutions. In such a dynamic landscape, having strong intellectual property protection is a crucial factor that sets products apart. The trademark for V Conceive not only affirms the uniqueness of our solution but also opens up significant opportunities for medical device distributors and investors seeking reliable, innovative products in reproductive health. Here’s what makes V Conceive stand out: 💡 Non-invasive & easy to use 💡 Affordable and accessible 💡 Compliant with international regulatory standards 🎯 For Medical Device Distributors: This is your chance to partner with a trusted name in reproductive technology, expand your portfolio, and tap into the growing demand for at-home medical solutions. 🎯 For Investors: With Subhag’s commitment to quality and innovation, V Conceive is poised for rapid adoption in both established and emerging markets, offering a high-growth potential. If you’re looking to learn more about distribution or investment opportunities, reach out today. Let’s shape the future of reproductive health together! 👇 Comment below or send a message to connect! #ReproductiveHealth #HealthcareInnovation #MedicalDevices #InvestmentOpportunity #HealthTech #FertilitySolutions #BusinessGrowth

"Diagnostics Firm Redcliffe Labs Raises $42M in Series C Round" Redcliffe Labs, an omnichannel diagnostics service provider, has secured $42 million in Series C funding, led by Denmark's Investment Fund for Developing Countries (IFU) with a $20 million investment, followed by existing investor LeapFrog Investments with $15 million. The remaining capital came from existing shareholders HealthQuad and Spark Growth Ventures.This funding will fuel Redcliffe's expansion plans, focusing on deepening its presence in Tier-II and Tier-III cities across India. The company plans to open more labs and collection centers, expand its home collection network, and pursue strategic partnerships and acquisitions . Redcliffe's goal is to democratize access to high-quality, affordable, and accurate diagnostics for every Indian, particularly in underserved populations. The company currently operates over 80 labs, processes tests from 2,000 collection centers, and has a network of 1,000 phlebotomists across 220 cities in India . SOURCE- Business Standard #RedcliffeLabs, #SeriesCFunding, #HealthcareFunding, #DiagnosticsIndustry #IndianHealthcare , #StartupFunding , #HealthTech ,#MedicalDiagnostics #IndiaExpansion #HealthcareInnovation #FundingNews #StartupNews #IndianStartupEcosystem #HealthcareStartup

Fortis Bengaluru Hits 1,000 Robot-Aided Urological Procedures Milestone: Bengaluru, has reached an impressive milestone by performing over 1000 Robot-aided surgeries using the Da Vinci Xi Robotic Surgical System at Bannerghatta Road highlighting the hospital’s expertise and commitment to advanced surgical techniques. This accomplishment not only underscores the hospital’s capabilities but also its role in leading the adoption of cutting-edge technology in urology. In addition, the introduction of the Da Vinci X system at Fortis Cunningham Road signifies the hospital’s ongoing investment in expanding access to state-of-the-art surgical options. Fortis Hospital, Bengaluru is at the forefront of integrating robotic technology into their surgical practices, which has led to improved patient outcomes, shorter recovery times, and increased precision in complex procedures. The Urology Team led by Dr. Mohan Keshavamurthy, has successfully performed more than 1,000 robotic surgeries over the past 79 months, since the installation of the Da Vinci surgical system at Fortis Bannerghatta Road in 2018. These surgeries span a broad range of complex procedures across Uro-Oncology, Uro-Gynaecology, Reconstructive Urology, and Kidney Transplantation. The surgeries conducted via Da Vinci Xi Robot include 92 Robotic Kidney Transplants, 398 Nerve-Sparing Robotic Radical Prostatectomies, 282 Robotic Complex Partial Nephrectomies and 54 Pediatric Robotic Procedures, amongst others. One such case is that of Patient Amar (name changed), a 50-year-old man who underwent multiple procedures in his hometown Kolkata, for a stone in the Ureter. During the surgical procedure, there were intra-operative complications that led to a traumatic injury to the ureter. A surgical procedure to examine the abdominal cavity was performed, however the ureter could not be repaired. As a result of the injured ureter, a tube was inserted to drain urine from the kidney (Nephrostomy). These complications led to recurrent urinary tract infections in the patient, requiring multiple ICU admissions. The patient was eventually airlifted from Kolkata to Fortis Bannerghatta Road, Bengaluru, where doctors successfully performed robot-assisted laparoscopic surgery to repair the ureteric injury. Source- Business News #technology #Robotics